FDA approves ‘game-changing’ pancreatic cancer drug
In a late-stage trial, people who got Revolution Medicines’ Rasonque, or daraxonrasib, lived about twice as long as people who got standard care....
Redirecting to full article...
In a late-stage trial, people who got Revolution Medicines’ Rasonque, or daraxonrasib, lived about twice as long as people who got standard care....
Redirecting to full article...